Patents Assigned to Prolx Pharmaceuticals Corp.
  • Wortmannin Analogs and Methods of Using Same in Combination with Chemotherapeutic Agents
    Publication number: 20110110941
    Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
    Type: Application
    Filed: November 8, 2010
    Publication date: May 12, 2011
    Applicants: PROLX PHARMACEUTICALS CORP., Arizona Board of Regents on behalf of the University of Arizona, University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Garth POWIS, Peter WIPF, Lynn KIRKPATRICK
  • Methods of identifying respondents to hypoxia inducible factor 1-? inhibitors
    Patent number: 7629128
    Abstract: This invention relates to methods of measuring HIF expression and activity, as well as measuring inhibition of HIF following administration of an HIF inhibitor useful in treating HIF related diseases. The present invention further relates to methods of identifying individuals who will respond to HIF inhibitors. The invention also relates to methods of monitoring a patient response to a given dosage of an HIF inhibitor. The invention also includes assays and kits for performing the methods described herein.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: December 8, 2009
    Assignee: Prolx Pharmaceuticals Corp.
    Inventors: Lynn Kirkpatrick, Linda Anne Pestano
  • Wortmannin Analogs and Methods of Using Same in Combination with Chemotherapeutic Agents
    Publication number: 20090087441
    Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
    Type: Application
    Filed: September 23, 2008
    Publication date: April 2, 2009
    Applicants: Prolx Pharmaceuticals Corp., Arizona Board of Regents, acting on hehalf of The University of Arizona, The University of Pittsburgh
    Inventors: Lynn Kirkpatrick, Garth Powis, Peter Wipf
  • Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
    Patent number: 7446124
    Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: November 4, 2008
    Assignees: Prolx Pharmaceuticals Corp., The University of Pittsburgh, Arizona Board of Regents, Acting on Behalf of the University of Arizona
    Inventors: Lynn Kirkpatrick, Garth Powis, Peter Wipf
  • N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
    Patent number: 7399785
    Abstract: This invention relates to compounds which are N-oxides and derivatives thereof, as well as their use to treat HIF related diseases.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: July 15, 2008
    Assignee: Prolx Pharmaceuticals Corp.
    Inventors: Lynn Kirkpatrick, Garth Powis, Sarah J. Welsh
  • Wortmannin analogs and methods of using same
    Patent number: 7081475
    Abstract: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well as tumor formation in a subject are described herein.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: July 25, 2006
    Assignees: Prolx Pharmaceuticals Corp., Arizona Board of Regents, Acting on behalf of the University of Arizona, University of Pittsburgh
    Inventors: Garth Powis, Wipf Peter